Decoy Therapeutics (NASDAQ:DCOY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Decoy Therapeutics (NASDAQ:DCOY) from a sell rating to a hold rating in a report published on Saturday.

A number of other research analysts also recently issued reports on the company. Weiss Ratings assumed coverage on Decoy Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. LADENBURG THALM/SH SH started coverage on Decoy Therapeutics in a research report on Friday, January 23rd. They issued a “buy” rating and a $2.50 target price for the company. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.50.

Decoy Therapeutics Trading Down 5.5%

DCOY stock opened at $0.70 on Friday. Decoy Therapeutics has a 12-month low of $0.51 and a 12-month high of $34.65. The company has a market capitalization of $4.47 million, a P/E ratio of -0.02 and a beta of 0.39.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.